← Leaderboards
Corinne Elizabeth Augelli-Szafran
University Of Alabama At Birmingham
$5,696,528
Attributed
$11,384,616
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,384,616 · 6
By mechanism
R01$8,246,104 · 3
UG3$2,180,708 · 1
U54$685,252 · 1
R21$272,552 · 1
Top collaborators
- Jun Zhu6 shared
- Sue Chin Lee4 shared
- Gabor J Tigyi4 shared
- Raul Martin Torres4 shared
- Mohammad Athar3 shared
- Anita Borton Hjelmeland1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Anupam Agarwal$17,840,868
- Mark J Suto$3,119,036
- Aurelio Antonio Galli$19,438,938
- Emily Jorgensen$225,897
- Faraz Ali Sultan$167,242
Others in their field
Other Emerging Leaders on “Pharmaceutical Chemistry”
- John Damon Chodera · Sloan-Kettering Inst Can Research$49,367,180
- Xinhua Li · Nano Terra, Inc.$23,903,965
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
- Thomas Dick · Rbhs-New Jersey Medical School$14,469,725
- Timothy M Willson · University Of Cape Town$13,282,594
- Bruce Blough · Research Triangle Institute$12,018,268
Research focus
Pharmaceutical ChemistryIn VivoDesignIn VitroLead OptimizationDrug KineticsPropertySmall MoleculeLeadDockingSolubilityAnalogResearch PersonnelStructure-Activity RelationshipDrug DesignImpairmentTransgenic MiceBindingPharmaceutical PreparationsMetabolicIncidenceMediatingProteinsComplex
Grant awards (16)
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$729,283
R01 · FY2025 · CA
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals$521,500
UG3 · FY2025 · AR · contact PI
Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS$927,795
R01 · FY2024 · DA · contact PI
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals$824,145
UG3 · FY2024 · AR · contact PI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$712,726
R01 · FY2024 · CA
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals$835,063
UG3 · FY2023 · AR · contact PI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$810,231
R01 · FY2023 · CA
Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS$791,611
R01 · FY2023 · DA · contact PI
Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS$148,255
R01 · FY2023 · DA · contact PI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$861,845
R01 · FY2022 · CA
Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS$784,203
R01 · FY2022 · DA · contact PI
Core 3: Drug Discovery and Development Core$685,252
U54 · FY2022 · ES · contact PI
Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS$794,235
R01 · FY2021 · DA · contact PI
Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS$805,690
R01 · FY2020 · DA · contact PI
Development of Mu Agonist Delta Antagonist Opioids as Analgesics for Chronic Pain$880,230
R01 · FY2019 · DA · contact PI
Identification of Glucose Transporter 3 Inhibitors for Glioblastoma Treatment$272,552
R21 · FY2017 · NS